Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016

NCT02668666 is registered in ClinicalTrials.gov with Oana Danciu, MD as lead sponsor.

NCT NCT02668666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02668666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single Arm Phase II Study of Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016
Lead sponsor
Oana Danciu, MD
Phase
Phase 2
Overall status
Completed
Start date
February 1, 2017
Completion date
October 24, 2023
Enrollment
49 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

estrogen receptor positive breast cancer, hormone receptor positive malignant neoplasm of breast, human epidermal growth factor 2 negative carcinoma of breast, metastatic breast cancer, progesterone receptor positive tumor